Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01528111 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
A Phase 1 study, sponsored by Lexicon Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
NCT01528111 is a Phase 1 study that has completed, run by Lexicon Pharmaceuticals. The registered enrollment target is 63 participants.
The verdict
NCT01528111, a Phase 1 study, has completed, sponsored by Lexicon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
Study Summary
This Phase 1/2a study is intended to assess the safety, tolerability, and effects on intraocular pressure of two dose levels and two dose frequencies of LX7101 when administered topically in the eyes of patients diagnosed with primary open-angle glaucoma or ocular hypertension.
Interventions
- DRUG LX7101 (0.125%)
- DRUG LX7101 (0.25%)
- DRUG LX7101 Vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2012-03 |
| Est. Completion | 2012-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01528111
The ClinicalTrials.gov registry entry for NCT01528111 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lexicon Pharmaceuticals, which has 56 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which LX7101 (0.125%) is the first listed.
NCT01528111 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01528111 about?
NCT01528111 is a clinical study titled "Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension". This Phase 1/2a study is intended to assess the safety, tolerability, and effects on intraocular pressure of two dose levels and two dose frequencies of LX7101 when administered topically in the eyes of patients diagnosed with primary open-angle glaucoma or ocular hypertension.
What is the current status of trial NCT01528111?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2012-03. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01528111?
The interventions under investigation include: LX7101 (0.125%) (DRUG), LX7101 (0.25%) (DRUG), LX7101 Vehicle (DRUG).
Who is sponsoring clinical trial NCT01528111?
This trial is sponsored by Lexicon Pharmaceuticals, which has 56 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.